RE:RE:RE:RE:RE:Deliberate ObfuscationLegit62 wrote: Totally agree Infinity, i think we are just at the beginning of knowing what TLD1433 can really do, i am a long holder and have accumulated many shares like all of you long holders and am also hoping we dont sell ourselves short, also think we are within 6 months of BTD and AA, am curious to see what is presented on the 27TH and at AGM, also would like to know more about The Li Ka Shing relationship, cause as Skyes1 says , he believes this holds the key to our moving foward .
Osmium molecules 2017 Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase is committed to expanding our Phase Ib clinical research program to include new oncological targets, using both our Ruthenium (TLD-1433) and Osmium ((TLD-1822, TLD-1824 and TLD-1829) based PDCs. We look forward to presenting this research to the international scientific and medical communities.” 1633 15% more gbm Sherri McFarland, Ph.D., Professor, Department of Chemistry and Biochemistry, The University of North Carolina at Greensboro stated that, “TLD-1633 is a natural progression of the research work completed by our research labs in the development of TLD-1433. TLD-1633 has shown even stronger safety and efficacy in our labs than TLD-1433, and I am delighted to work with Theralase to optimize and expand their licenced PDC program, as we embark on additional cancer indications.” Were you guys asleep for 5 years......
This whole thing..... oh the TLD-1433... we're just at the beginning.......... NO... we are at the END of Tld-1433........
It's time to get PAID for Bladder and move into Ruthenium and other molecules...
Do a massive licensing or buyout for ACT and the technology.......
Photodynamic therapy has proven it's 'matured' to become attractive to big pharma.